{"schema":"sb.node.v1","id":"sb:e/60ec953a2d5ebc1b36a7811b","kind":"entity","label":{"text":"priority review","locale":"en"},"identity":{"anchor":"label:en:priority review","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T23:27:45.667496+00:00","snapshot":"deploy 2e5ddc12e7da6a156749e183c3b335c8968e59b7"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":50,"separatePublishers":21,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"partial","share":0.22,"named":11,"of":50,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn from the former only","blind":["only 22% of the 50 documents measured name the subject in their own text; the rest mention it in passing, so standing.evidence.supporting overstates coverage about it"]}},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-07-11","to":"2026-10-10","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.64: about 36% of mentions carry no typed assertion"]}},"dimensions":{"domains":["fda_decisions","biotech_pharma"],"activeDays":28,"assertions":{"regulatory-approval":31,"election":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":9,"byKind":{"observation":9},"withheld":{"state":"withheld","count":2,"reason":"2 receipts withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/73e01f206479bb60aa35a3da","kind":"observation","label":"AllSci News · 2026-10-08 · Ultragenyx to sell FDA priority review voucher for USD 210 million","url":"https://allsci.com/news/biotech/priority-review-voucher-ultragenyx-agrees-to-sell/"},{"id":"sb:o/bd4b7b056485238dd504d714","kind":"observation","label":"AllSci News · 2026-10-07 · BridgeBio's oral infigratinib gets US FDA Priority Review in achondroplasia","url":"https://allsci.com/news/biotech/infigratinib-achondroplasia-fda-grants-priority/"},{"id":"sb:o/959b3af699eb16d07931dfba","kind":"observation","label":"AllSci News · 2026-09-30 · Roche’s fenebrutinib gets FDA priority review for RMS and PPMS","url":"https://allsci.com/news/biotech/fenebrutinib-fda-approval-ms-accepts-roches/"},{"id":"sb:o/8b99a1ff1e36270fb40ef63b","kind":"observation","label":"AllSci News · 2026-09-30 · AstraZeneca wins Priority Review for Imfinzi-EV regimen in bladder cancer","url":"https://allsci.com/news/biotech/imfinzi-enfortumab-bladder-cancer-fda-grants/"},{"id":"sb:o/7ff2cbb5ed1fc4fbfd91a488","kind":"observation","label":"MarketBeat News Feed · 2026-09-13 · AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears","url":"https://www.marketbeat.com/instant-alerts/event-astrazeneca-copd-drug-cuts-exacerbations-as-fda-priority-review-nears-2026-09-13/"},{"id":"sb:o/46bf82f169715411dd00f713","kind":"observation","label":"FDA · 2026-09-04 · Tropical Disease Priority Review Voucher Program","url":"http://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/tropical-disease-priority-review-voucher-program"},{"id":"sb:o/37a695e8a65b4e6cd164bf69","kind":"observation","label":"Endpoints News · 2026-10-07 · Ultragenyx sells PRV for $210M and still has another to monetize","url":"https://endpoints.news/ultragenyx-sells-prv-for-210m-and-still-has-another-to-monetize/"},{"id":"sb:o/b87f0c38ebf2a8fc4ce03811","kind":"observation","label":"The Clinical Trial Vanguard · 2026-09-24 · FDA Approves Lyrfigtu for FGFR2-Rearranged Cholangiocarcinoma","url":"https://www.clinicaltrialvanguard.com/news/fda-approves-lyrfigtu-for-fgfr2-rearranged-cholangiocarcinoma/"},{"id":"sb:o/3489e68bac94fc67ef4efb7b","kind":"observation","label":"PR Newswire · 2026-09-22 · Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding","url":"https://www.prnewswire.com/news-releases/decoy-therapeutics-exploring-pan-filovirus-program-via-fda-animal-rule-pathway-and-non-dilutive-funding-302885511.html"}],"cursor":null,"order":"newest first; we keep the 9 newest receipts for this entity whose own title or summary lead (the entity graph's test) names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with fda (46 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/8ea7032632f023bb0a4511c9"},{"kind":"relation","label":"co-mentioned with drug administration (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2696f67b1ee721e640a6e677"},{"kind":"relation","label":"co-mentioned with orphan drug (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4614202196a42821c7aac647"},{"kind":"relation","label":"co-mentioned with breakthrough therapy (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/a541feff23370c6c4ff5ed2c"},{"kind":"relation","label":"co-mentioned with fda-approved (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b74c2373f02049a3bab45042"},{"kind":"relation","label":"co-mentioned with clinical trial (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/77a5246eccbbadb7de663f55"},{"kind":"relation","label":"co-mentioned with adverse events (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/f4fe3c2bb1ff17f61641ddfb"},{"kind":"relation","label":"co-mentioned with rare pediatric disease (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/cc21bd2f9492ca8873bfe025"},{"kind":"relation","label":"co-mentioned with oncology center (8 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/a91d0566e839d2a32ff94c8f"},{"kind":"relation","label":"co-mentioned with u.s. food (8 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b60834b31f8bd1584ee1a6a9"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/60ec953a2d5ebc1b36a7811b","mcp":"traverse {\"id\":\"sb:e/60ec953a2d5ebc1b36a7811b\"}","page":"/entity/priority-review/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/60ec953a2d5ebc1b36a7811b\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/60ec953a2d5ebc1b36a7811b\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/60ec953a2d5ebc1b36a7811b\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/60ec953a2d5ebc1b36a7811b\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}